- Home
- VIVS vs CDIO Comparison
VIVS vs CDIO Comparison
Compare VIVS & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VIVS | CDIO |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | 9 | 9 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 5.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | VIVS | CDIO |
|---|---|---|
| Price | $1.68 | $2.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 67.3K | ★ 4.3M |
| Earning Date | 06-03-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $42.38 | $171,906.75 |
| Revenue Next Year | $15.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.42 | $0.18 |
| 52 Week High | $5.30 | $7.91 |
Technical Indicators
Market Signals| Indicator | VIVS | CDIO |
|---|---|---|
| Relative Strength Index (RSI) | 37.47 | 38.47 |
| Support Level | N/A | $1.26 |
| Resistance Level | $2.08 | $4.24 |
| Average True Range (ATR) | 0.09 | 0.79 |
| MACD | -0.02 | -0.39 |
| Stochastic Oscillator | 1.82 | 1.39 |
Price Performance
Historical ComparisonAbout VIVS VivoSim Labs Inc.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
About CDIO Cardio Diagnostics Holdings Inc.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.